Videos

An expert shares information on a pair of noteworthy active trials in breast cancer that patients should be aware of.

An expert explains what biliary tract cancers are and the current landscape of treatment as well as future advancements.

Dr. Gabriel A. Brooks discusses what DPD deficiency is and why it is important for patients with cancer receiving 5-FU or Xeloda to be aware of it.

An expert explains that the GAP regimen did not improve overall survival in advanced biliary tract cancer versus the doublet and increased severe side effects.

Dr. Laurence Albiges discusses triplet therapies, highlighting which patients with RCC may garner the most benefit with this treatment intensification.

Dr. Chandler Park discusses the importance of genetic testing and personalized care in patients with genitourinary cancers.

An expert explains the importance of genetic testing in metastatic colorectal cancer, as recent FDA approval highlights its role in guiding targeted treatments.

Dr. Catherine Wu discussed the unique aspects of clear cell renal cell carcinoma and the challenges of targeting it with a vaccine.

Dr. Nataliya Uboha explained the benefit of treatment with Krazati combined with Erbitux in KRAS G12C–mutant metastatic colorectal cancer.

Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.

Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.

Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.

Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.

There are differences in prostate cancer treatment intensification adoption between academic and nonacademic physicians.

Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on disease progression.

Dr. Guru P Sonpavde discusses updated data from studies like EV-302 and CheckMate 274 for patients with urothelial cancer at the 2025 ASCO GU meeting.

Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in previously untreated mantle cell lymphoma.

Dr. Ritu Salani discusses how patients with cervical cancer can advocate for their health and collaborate with their medical team to ensure the best care.

Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or -ultralow breast cancer.

Dr. Suneel Kamath discusses the ALASCCA study in colorectal cancer and highlighted the importance of next-generation sequencing and testing.

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

In a clinical trial, patients treated with a kidney cancer vaccine remained cancer-free after a median of nearly three years.

Dr. John Oertle discusses the key benefits to come from patients with cancer connecting with support networks, advocacy groups and resources.

Dr. Gabriel A. Brooks discusses the recent FDA product labeling update for Xeloda and 5-FU which aims to highlight risks associated with DPD deficiency.

A panelist discusses how polycythemia vera (PV) impacts daily life and lifestyle management, including beneficial changes patients can make, available support resources and educational materials while offering guidance for living with the condition.

Dr. Alan Tan spoke with CURE® about what patients with kidney cancer and providers who treat it may be able to learn from ctDNA.

Dr. Jonathan R. Strosberg, discussed results of the CABINET trial evaluating Cabometyx versus placebo in advanced gastrointestinal NETs.

Dr. David A. Braun delved into the molecular factors which drive exceptional responses to immunotherapy in metastatic clear cell renal cell carcinoma.

A panelist discusses how caregivers can support patients with polycythemia vera (PV) by helping track symptoms, managing medical appointments and recognizing warning signs that require physician intervention.

Dr. Anna Arthur discusses the NOURISH trial, which aims to address food insecurity and malnutrition in patients with blood cancers undergoing treatment.